Title : Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.

Pub. Date : 2020 Oct

PMID : 32747013






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 OBJECTIVE: To examine whether blocking multiple points of the angiogenesis pathway by addition of sorafenib, a multi-kinase inhibitor against VEGFR2/3, Raf, c-Kit, and PDGFR, to bevacizumab would yield clinical activity in ovarian cancer (OvCa). Sorafenib kinase insert domain receptor Homo sapiens